HemoBioTech to Present at NanoTX '06

    DALLAS, Sept. 27 /PRNewswire-FirstCall/ -- HemoBioTech, Inc. (OTC
 Bulletin Board: HMBT) announced today that Dr. Arthur P. Bollon, Chairman &
 CEO of HemoBioTech will make a presentation at the NanoTX '06 conference on
 September 27-28, 2006 in Dallas, Texas. He will address the quest for a
 substitute for human blood and present key features of HemoTech(TM), the
 novel blood substitute under development by HemoBioTech.
     Ross Perot will be the keynote speaker at the conference, which will
 also include His Royal Highness The Duke of York. The conference will
 involve over 150 nanotechnology specialists from 30 different countries and
 a special session involving six Nobel Laureates from various disciplines.
     "We are very excited about being asked to speak at this prestigious
 conference," said Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech.
 "This will be an excellent opportunity to share our novel approach to the
 quest for a blood substitute which is employed in HemoTech(TM)."
     About HemoBioTech, Inc.
     HemoBioTech is engaged in the commercial development of HemoTech(TM), a
 novel human blood substitute technology exclusively licensed from Texas
 Tech University Health Sciences Center. HemoTech(TM) is chemically modified
 bovine hemoglobin, which not only carries oxygen in the blood, but can also
 induce erythropoiesis (red blood cell production). The hemoglobin is
 modified with ATP, adenosine and GSH. The Company believes that
 HemoTech(TM) may possess properties that diminish the intrinsic toxicities
 which have plagued other attempts at developing blood substitutes, based
 upon pre-clinical and initial human clinical trials undertaken outside the
 U.S. by prior holders of this technology. HemoTech(TM) is being subjected
 to further studies and testing to confirm and possibly expand on these
 results. HemoTech(TM) is being developed to help reduce or eliminate the
 danger resulting from acute blood loss in trauma, as well as for other
 conditions. Corporate headquarters are located at J. P. Morgan
 International Plaza, 14221 Dallas Parkway, Suite 1400, Dallas, Texas 75254.
 The Company website is http://www.hemobiotech.com . For further information
 contact Dr. Arthur Bollon at 214-540-8411 or abollon@hemobiotech.com .
     Safe Harbor Statement
     Except for historical information, the matters discussed in this news
 release may be considered "forward-looking statements" within the meaning
 of Section 27A of the Securities Act of 1933, as amended, and Section 21E
 of the Securities Exchange Act of 1934, as amended. Such statements include
 declarations regarding the intent, belief or current expectations of
 HemoBioTech and its management and are valid only as of today, and we
 disclaim any obligation to update this information. These statements are
 subject to known and unknown risks and uncertainties that may cause actual
 future experience and results to differ materially from the statements
 made. Factors that might cause such a difference include, among others the
 successful pre- clinical development, the successful completion of clinical
 trials, the FDA review process and other governmental regulation,
 pharmaceutical collaborator interest and ability to successfully develop
 and commercialize drug candidates, competition from other pharmaceutical
 companies, product pricing and third party reimbursement, and other factors
 which are included in HemoBioTech's Annual Report on Form 10-KSB for the
 year ended December 31, 2005, as amended, and HemoBioTech's other reports
 filed with the Securities and Exchange Commission.
 
 

SOURCE HemoBioTech, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.